Wilder Fulford

Wilder Fulford is the founder and Managing Director of The Fulford Group, a boutique investment bank focused on life sciences and healthcare M&A, corporate finance, partnering, and licensing advice. The firm states that Fulford has advised boards, management teams, and owners for more than 30 years across bulge-bracket investment banks and specialist boutiques.

Fulford founded The Fulford Group in 2015. Before that, he was a Partner at Torreya Partners and founder of its Europe office from 2010 to 2015. His earlier senior investment-banking roles included Head of Europe Healthcare M&A at Deutsche Bank from 2006 to 2010, Head of Europe Healthcare Investment Banking at Bank of America from 2002 to 2006, Head of Europe Healthcare and Materials M&A at Merrill Lynch from 1999 to 2002, and Head of Healthcare M&A at Salomon Brothers from 1994 to 1999.

Earlier in his career, Fulford was an Associate in venture capital and M&A at James D. Wolfensohn Inc. from 1986 to 1994. He holds a Ph.D. in Molecular Biology from The Rockefeller University, awarded in 1986, and a BSc in Biochemistry and English from the University of Toronto, awarded in 1980.

The Fulford Group reports that Fulford has worked on more than 100 completed financing and M&A transactions with notional value above $100 billion. The available primary sources position him as an investment banker and transaction advisor, not as a public angel investor with a disclosed personal angel portfolio.

• The Fulford Group focuses on independent transaction advice and execution for life sciences, healthcare, and selected other industries.
• The firm describes its approach as “thoughtful solutions customized to meet your transaction demands.”
• Its sector emphasis includes clinical and commercial-stage assets in medtech and pharma.
• The firm highlights experience in healthcare M&A, life sciences and medtech partnering, licensing deals, royalty monetization, financing, and corporate finance.
• The firm says it takes on “only selected assignments,” allowing senior attention and avoiding conflicts.
• The Fulford Group’s stated target clients include companies, entrepreneurs, and investors, especially where a transaction requires healthcare sector knowledge, asset valuation, or relationships across pharma and medtech business development.